The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1237
ISSUE1237
June 19, 2006
Transdermal Methylphenidates (Daytrana) for ADHD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Transdermal Methylphenidates (Daytrana) for ADHD
June 19, 2006 (Issue: 1237)
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.